Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone mineral density and thyroid hormone therapy.

C Ribot1, F Tremollieres, J M Pouilles

  • 1UF Maladies Osseuses et Métaboliques; Service d'Endocrinologie Chu Purpan, Toulouse, France.

Clinical Endocrinology
|August 1, 1990
PubMed
Summary

Thyroid replacement therapy for hypothyroidism may temporarily decrease bone mineral density (BMD) in the first year. However, bone loss appears reversible, with no increased fracture risk observed in long-term patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of women with abnormal uterine bleeding: Clinical practice guidelines of the French National College of Gynaecologists and Obstetricians (CNGOF).

European journal of obstetrics, gynecology, and reproductive biology·2023
Same author

[Women with a very high risk of breast cancer: Contraceptives, hormonal replacement therapy use and personalized screening].

Gynecologie, obstetrique, fertilite & senologie·2023
Same author

Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d'Etude sur la Ménopause et le Vieillissement (GEMVi) Clinical Practice Guidelines.

Maturitas·2022
Same author

Quality of life of patients with bilateral oophorectomy before the age of 45 for the treatment of endometriosis.

Maturitas·2022
Same author

[Management of women with abnormal uterine bleeding: Clinical practice guidelines of the French National College of Gynecologists and Obstetricians (CNGOF)].

Gynecologie, obstetrique, fertilite & senologie·2022
Same author

[Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines (Short version)].

Gynecologie, obstetrique, fertilite & senologie·2021

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Hypothyroidism affects bone metabolism.
  • Thyroid hormone replacement is standard treatment.
  • The impact of treatment on bone mineral density (BMD) requires further investigation.

Purpose of the Study:

  • To prospectively evaluate changes in femoral and vertebral BMD in hypothyroid patients receiving L-thyroxine replacement therapy.
  • To compare BMD evolution in treated versus untreated hypothyroid individuals.
  • To assess BMD in patients on long-term suppressive or replacement L-thyroxine doses.

Main Methods:

  • Prospective study of hypothyroid patients undergoing L-thyroxine treatment.
  • Measurement of bone mineral density (BMD) at femoral neck and vertebrae.

Related Experiment Videos

  • Cross-sectional analysis of BMD in patients on long-term therapy with varying L-thyroxine doses.
  • Monitoring of urinary calcium/creatinine and plasma osteocalcin levels.

    • Main Results:

    • A significant decrease in vertebral and femoral BMD was observed within the first year of L-thyroxine treatment (P < 0.01).
    • This bone loss was independent of age or menopausal status.
    • Fasting urinary calcium/creatinine and plasma osteocalcin levels increased significantly during treatment.
    • Vertebral BMD in long-term treated patients was comparable to age-matched controls.

    Conclusions:

    • Appropriate thyroid hormone replacement therapy may lead to a transient reduction in BMD during the initial year of treatment.
    • The observed bone mass reduction appears reversible, potentially due to compensatory bone formation.
    • Long-term treatment does not seem to increase fracture risk, suggesting a favorable long-term bone health profile.